EdwardDAguraMD

Oncology • Dallas, TX

Hematologic Oncology

Director, Marrow Transplantation, Baylor U. Medical Center, Dallas TX

Join to view full profile

Dr. Agura is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Agura's full profile

Already have an account?

Office
3410 Worth St
Suite 300
Dallas, TX 75246
Phone+1 214-370-1513

Fax+1 214-370-1585

Education & Training

Boston University Medical CenterResidency, Internal Medicine, 1983 - 1986
Boston University Medical CenterResidency, Internal Medicine, 1982 - 1985
Boston University Medical CenterInternship, Internal Medicine, 1982 - 1983
New York University School of MedicineClass of 1982
University of WashingtonFellowship, Medical Oncology

Certifications & Licensure

TX State Medical License 1994 - 2021

Clinical Trials

Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
Completed
Phase 3
Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Completed
Phase 3
Study of Stem Cell Transplant for Leukemia and Myelodysplastic Syndromes Using Clofarabine and Busulfan Regimen Start of enrollment: 2007 Mar 01
Completed
Phase 2
Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma Start of enrollment: 2010 Jul 14
Completed
Phase 3
Selecting a Favorable KIR Donor in Unrelated HCT for AML Start of enrollment: 2011 Jun 01
Completed
Not Applicable
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3
Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) Start of enrollment: 2011 Jun 01
Terminated
Phase 3
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma Start of enrollment: 2013 Jun 01
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

22 citations
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades.
Jason P. Cooper, Barry E. Storer, Noa Granot, Boglarka Gyurkocza, Mohamed L. Sorror
Haematologica. 2020-06-04
25 citations
Three‐year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma
Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura
British Journal of Haematology. 2020-02-12
11 citations
Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience.
Mazyar Shadman, David G. Maloney, Barry E. Storer, Brenda M. Sandmaier, Thomas R. Chauncey
Bone Marrow Transplantation. 2020-01-01

Journal Articles

Five-Year PFS from the AETHERA Trial of Brentuximab Vedotin for Hodgkin Lymphoma at High Risk of Progression or Relapse
Patrick Stiff, Edward Agura, Craig H Moskowitz, John Sweetenham, Auayporn Nademanee, Veronika Bachanova, Blood